Recurrent or Metastatic Breast Cancer

Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

DP
Daehwa PharmaceuticalKorea - Gangwon
2 programs
1
1
Oral paclitaxelPhase 2/31 trial
DHP107Phase 21 trial
Active Trials
NCT03326102Completed72Est. Dec 2022
NCT03315364Active Not Recruiting549Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daehwa PharmaceuticalOral paclitaxel
Daehwa PharmaceuticalDHP107

Clinical Trials (2)

Total enrollment: 621 patients across 2 trials

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Start: Dec 2017Est. completion: Dec 2025549 patients
Phase 2/3Active Not Recruiting

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

Start: Jul 2018Est. completion: Dec 202272 patients
Phase 2Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space